Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

CEFOXITIN SODIUM

All injection strengths: not a benefit

Other products in the same Health Canada class (J01D, J01DC) — coverage varies; not interchangeable

  • Cefprozil (Ran-Cefprozil): general benefit, Not a benefit
  • Cefuroxime axetil (Ceftin): general benefit, Not a benefit
  • Cefadroxil (Duricef): general benefit, Not a benefit
  • Cefixime (Suprax): general benefit
  • Ceftriaxone (Rocephin): general benefit, Not a benefit
  • Cephalexin (Ceporex): general benefit, Not a benefit

1 more in the class list below

Cefoxitin for Injection USP · DIN 02128187 · 1g/Vial · powder for injection, vial

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Cefoxitin for Injection USP · DIN 02128187 Manufacturer: Teva Canada Limited; listing date 2012-04-24 Health Canada: Marketed since 2013-11-22 · brand CEFOXITIN FOR INJECTION · ATC J01DC01 CEFOXITIN · form Powder for solution · route Intravenous, Intramuscular · ingredients CEFOXITIN (CEFOXITIN SODIUM) 1 G/VIAL · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Cefoxitin for Injection USP: Formulary list price $10.6000/unit (unit not stated in source; not the patient's cost)

Ministry pays: $10.6000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19200 · Verify on the e-Formulary ↗ (DIN 02128187)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02128187). DIN 02128187: Cefoxitin for Injection USP Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 081228119; group id 39; item number 0079; lccId None; manufacturer id TEV Source form: Inj Pd-Vial Pk; strength: 1g/Vial Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $10.6000; ministry $10.6000 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02128187 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19200
Interchangeable products
Cefoxitin for Injection · DIN 02291711 · $10.6000 Mefoxin · DIN 00663697 · not recorded
Shortage status: resolved shortage (ended 2025-04-07); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02128187
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Cefoxitin for Injection USP · DIN 02128195 · 2g/Vial · powder for injection, vial

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Cefoxitin for Injection USP · DIN 02128195 Manufacturer: Teva Canada Limited; listing date 2012-04-24 Health Canada: Marketed since 2013-11-22 · brand CEFOXITIN FOR INJECTION · ATC J01DC01 CEFOXITIN · form Powder for solution · route Intravenous, Intramuscular · ingredients CEFOXITIN (CEFOXITIN SODIUM) 2 G/VIAL · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Cefoxitin for Injection USP: Formulary list price $21.2500/unit (unit not stated in source; not the patient's cost)

Ministry pays: $21.2500 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19201 · Verify on the e-Formulary ↗ (DIN 02128195)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02128195). DIN 02128195: Cefoxitin for Injection USP Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 081228120; group id 39; item number 0080; lccId None; manufacturer id TEV Source form: Inj Pd-Vial Pk; strength: 2g/Vial Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $21.2500; ministry $21.2500 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02128195 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19201
Interchangeable products
Cefoxitin for Injection · DIN 02291738 · $21.2500 Mefoxin · DIN 00663700 · not recorded
Shortage status: resolved shortage (ended 2026-03-18); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02128195
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Cefoxitin for Injection · DIN 02291711 · 1g/Vial · powder for injection, vial

Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2019-06-28 — choose a marketed DIN from the same-category list.Discontinued 2019-06-28 · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2019-06-28 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2019-06-28 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Cefoxitin for Injection · DIN 02291711 Manufacturer: Orchid Healthcare; listing date 2008-06-27 Health Canada: Cancelled post market since 2019-06-28 · brand CEFOXITIN FOR INJECTION USP · ATC J01DC01 CEFOXITIN · form Powder for solution · route Intramuscular, Intravenous · ingredients CEFOXITIN (CEFOXITIN SODIUM) 1 G/VIAL · company Pfizer canada ulc · schedule Prescription
Check this DIN again · Health Canada product record

Cefoxitin for Injection: Formulary list price $10.6000/unit (unit not stated in source; not the patient's cost)

Ministry pays: $10.6000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77707 · Verify on the e-Formulary ↗ (DIN 02291711)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02291711). DIN 02291711: Cefoxitin for Injection Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 081228119; group id 39; item number 0079; lccId None; manufacturer id ORC Source form: Inj Pd-Vial Pk; strength: 1g/Vial Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $10.6000; ministry $10.6000 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02291711 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77707
Interchangeable products
Cefoxitin for Injection USP · DIN 02128187 · $10.6000 Mefoxin · DIN 00663697 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02291711
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2019-06-28 — choose a marketed DIN from the same-category list.

Mefoxin · DIN 00663697 · 1g/Vial · powder for injection, vial

Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2003-02-07 — choose a marketed DIN from the same-category list.Discontinued 2003-02-07 · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2003-02-07 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2003-02-07 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Mefoxin · DIN 00663697 Manufacturer: Merck Sharp & Dohme Canada, Division of Merck Frosst Canada; listing date 2008-06-27 Health Canada: Cancelled post market since 2003-02-07 · brand MEFOXIN PWS 1GM/VIAL · ATC J01DC01 CEFOXITIN · form Powder for solution · route Intramuscular, Intravenous · ingredients CEFOXITIN (CEFOXITIN SODIUM) 1 G/VIAL · company Merck frosst canada & cie, merck frosst canada & co. · schedule Prescription
Check this DIN again · Health Canada product record

Mefoxin: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=8165 · Verify on the e-Formulary ↗ (DIN 00663697)

Source record
DIN 00663697: Mefoxin Raw flags: sec3=Y, sec3b=Y Item: 081228119; group id 39; item number 0079; lccId None; manufacturer id MSD Source form: Inj Pd-Vial Pk; strength: 1g/Vial Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00663697 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=8165
Interchangeable products
Cefoxitin for Injection · DIN 02291711 · $10.6000 Cefoxitin for Injection USP · DIN 02128187 · $10.6000
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00663697
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2003-02-07 — choose a marketed DIN from the same-category list.

Cefoxitin for Injection · DIN 02291738 · 2g/Vial · powder for injection, vial

Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2019-06-28 — choose a marketed DIN from the same-category list.Discontinued 2019-06-28 · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2019-06-28 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2019-06-28 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Cefoxitin for Injection · DIN 02291738 Manufacturer: Orchid Healthcare; listing date 2008-06-27 Health Canada: Cancelled post market since 2019-06-28 · brand CEFOXITIN FOR INJECTION USP · ATC J01DC01 CEFOXITIN · form Powder for solution · route Intramuscular, Intravenous · ingredients CEFOXITIN (CEFOXITIN SODIUM) 2 G/VIAL · company Pfizer canada ulc · schedule Prescription
Check this DIN again · Health Canada product record

Cefoxitin for Injection: Formulary list price $21.2500/unit (unit not stated in source; not the patient's cost)

Ministry pays: $21.2500 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77708 · Verify on the e-Formulary ↗ (DIN 02291738)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02291738). DIN 02291738: Cefoxitin for Injection Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 081228120; group id 39; item number 0080; lccId None; manufacturer id ORC Source form: Inj Pd-Vial Pk; strength: 2g/Vial Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $21.2500; ministry $21.2500 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02291738 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77708
Interchangeable products
Cefoxitin for Injection USP · DIN 02128195 · $21.2500 Mefoxin · DIN 00663700 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02291738
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2019-06-28 — choose a marketed DIN from the same-category list.

Mefoxin · DIN 00663700 · 2g/Vial · powder for injection, vial

Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2002-07-29 — choose a marketed DIN from the same-category list.Discontinued 2002-07-29 · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2002-07-29 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2002-07-29 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Mefoxin · DIN 00663700 Manufacturer: Merck Sharp & Dohme Canada, Division of Merck Frosst Canada; listing date 2008-06-27 Health Canada: Cancelled post market since 2002-07-29 · brand MEFOXIN PWS 2GM/VIAL · ATC J01DC01 CEFOXITIN · form Powder for solution · route Intramuscular, Intravenous · ingredients CEFOXITIN (CEFOXITIN SODIUM) 2 G/VIAL · company Merck frosst canada & cie, merck frosst canada & co. · schedule Prescription
Check this DIN again · Health Canada product record

Mefoxin: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=8164 · Verify on the e-Formulary ↗ (DIN 00663700)

Source record
DIN 00663700: Mefoxin Raw flags: sec3=Y, sec3b=Y Item: 081228120; group id 39; item number 0080; lccId None; manufacturer id MSD Source form: Inj Pd-Vial Pk; strength: 2g/Vial Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00663700 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=8164
Interchangeable products
Cefoxitin for Injection · DIN 02291738 · $21.2500 Cefoxitin for Injection USP · DIN 02128195 · $21.2500
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00663700
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2002-07-29 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (08:12:28 Other Antibiotics) and how they are covered

Matched class: 08:12:28 Other Antibiotics

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: CEFIXIME, CLINDAMYCIN PALMITATE Some products covered without a code (check the product listing): CEFADROXIL, CEFPROZIL, CEFTRIAXONE DISODIUM, CEFUROXIME AXETIL, CEPHALEXIN MONOHYDRATE, CLINDAMYCIN HCL, CLINDAMYCIN PHOSPHATE, TOBRAMYCIN, TOBRAMYCIN SULFATE 08:12:28 Other Antibiotics

CEFPROZIL

· 17 products · General benefit (11), Listed, not a benefit (6) · strengths: 125mg/5mL, 250mg/5mL, 250mg, 500mg · Oral Susp-100mL Pk, Oral Susp-75mL Pk, Tab

CEFUROXIME AXETIL

· 9 products · General benefit (7), Listed, not a benefit (2) · strengths: 125mg/5mL, 250mg, 500mg · Susp, Tab

CEFADROXIL

· 4 products · Listed, not a benefit (1), General benefit (3) · strengths: 500mg · Cap

CEFIXIME

· 4 products · General benefit · strengths: 20mg/mL, 400mg · Oral Susp, Tab

CEFTRIAXONE DISODIUM

· 16 products · Listed, not a benefit (3), General benefit (10), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 0.25g/Vial, 1g/Vial, 2g/Vial, 10g/Vial · Inj Pd-Vial Pk

CEPHALEXIN MONOHYDRATE

· 29 products · Listed, not a benefit (6), General benefit (23) · strengths: 250mg, 500mg, 25mg/mL, 50mg/mL · Cap, Pd for Oral Susp, Tab

CEFAZOLIN SODIUM

· 15 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 500mg/Vial, 1g/Vial, 10g/Vial · Inj Pd-Vial Pk, Inj Pd-Vial Pk (Preservative-Free)

CLINDAMYCIN HCL

· 20 products · Listed, not a benefit (2), General benefit (18) · strengths: 150mg, 300mg · Cap

CLINDAMYCIN PALMITATE

· 1 products · General benefit · strengths: 15mg/mL · Pd for Oral Susp

CLINDAMYCIN PHOSPHATE

· 2 products · General benefit (1), Listed, not a benefit (1) · strengths: 300mg/2mL · Inj Sol-2mL Pk

TOBRAMYCIN

· 3 products · Limited Use, codes 472 (1), General benefit (2) · strengths: 28mg, 300mg/5mL · Inh Pd-Cap, Inh Sol-5mL Pk

TOBRAMYCIN SULFATE

· 4 products · Listed, not a benefit (1), General benefit (3) · strengths: 80mg/2mL · Inj Sol-2mL Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 08:12:28 and 4 more
Full class listing Related classes: 08:12:04 Antifungals, 08:12:07 Carbapenems, 08:12:12 Erythromycins, 08:12:16 Penicillins, 08:12:24 Tetracyclines, 08:14:08 Azoles Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: bone and joint infections, gynecological infections, intra-abdominal infections, lower respiratory tract infections, septicemia, urinary tract infections
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. CEFTRIAXONE DISODIUM · Listed, not a benefit (3), General benefit (10), Off-Formulary Interchangeable, not an ODB benefit (3) • Lower Respiratory tract infections caused by E. coli, H. influenzae, K. pneumoniae and species, Staph. aureus, Strep. pneumoniae and species (excluding enterococci). PM: https://pdf.hres.ca/dpd_pm/00071552.PDF; date MAY 15, 2023; DIN 02289695; fetched 2026-09-10 Product monograph • Urinary tract infections (complicated and uncomplicated) caused by E. coli, Klebsiella species, P. mirabilis and P. vulgaris. PM: https://pdf.hres.ca/dpd_pm/00071552.PDF; date MAY 15, 2023; DIN 02289695; fetched 2026-09-10 Product monograph • Bone and Joint Infections caused by Staph. aureus, Strep. pneumoniae and Streptococcus species (excluding enterococci). PM: https://pdf.hres.ca/dpd_pm/00071552.PDF; date MAY 15, 2023; DIN 02289695; fetched 2026-09-10 Product monograph • Intra-Abdominal Infections caused by E.coli and K. pneumoniae. PM: https://pdf.hres.ca/dpd_pm/00071552.PDF; date MAY 15, 2023; DIN 02289695; fetched 2026-09-10 Product monograph CLINDAMYCIN PHOSPHATE · General benefit (1), Listed, not a benefit (1) • Gynecological infections including endometritis, pelvic cellulitis, vaginal cuff infections, non-gonococcal tubo-ovarian abscess, salpingitis, and pelvic inflammatory disease when caused by susceptible anaerobes or Chlamydia trachomatis. Clindamycin should be given in conjunction with an antibiotic of appropriate gram negative aerobic spectrum. PM: https://pdf.hres.ca/dpd_pm/00085906.PDF; date AUG 27, 2026; DIN 02230540; fetched 2026-09-10 Product monograph • Intra-abdominal infections including peritonitis and abdominal abscess when caused by susceptible anaerobes. Clindamycin should be given in conjunction with an antibiotic of appropriate gram negative aerobic spectrum. PM: https://pdf.hres.ca/dpd_pm/00085906.PDF; date AUG 27, 2026; DIN 02230540; fetched 2026-09-10 Product monograph • Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis) and susceptible anaerobes, where the bactericidal efficacy of clindamycin against the infecting organism has been determined in vitro at achievable serum levels. PM: https://pdf.hres.ca/dpd_pm/00085906.PDF; date AUG 27, 2026; DIN 02230540; fetched 2026-09-10 Product monograph • Bone and joint infections including osteomyelitis and septic arthritis when caused by sensitive strains of Staphylococcus aureus and anaerobes. PM: https://pdf.hres.ca/dpd_pm/00085906.PDF; date AUG 27, 2026; DIN 02230540; fetched 2026-09-10 Product monograph AMOXICILLIN & CLAVULANIC ACID · General benefit (22), Listed, not a benefit (3) • Lower Respiratory Tract Infections when caused by β-lactamase producing strains of H. influenzae, K. pneumoniae, S. aureus or Moraxella (Branhamella) catarrhalis. PM: https://pdf.hres.ca/dpd_pm/00084428.PDF; date 2026-04-24; DIN 01916874; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE TREATMENT For the treatment of the following infections when due to susceptible organisms: 1 - Intra-abdominal infections such as peritonitis and intra-abdominal abscess 2 - Gynecological infections such as endometritis and pelvic cellulitis 3 - Septicemia 4 - Urinary tract infections (including those caused by Serratia marcescens and Serratia spp.) 5 - Lower respiratory tract infections 6 - Bone and joint infections caused by Staphylococcus aureus 7 - Soft tissue infections such as cellulitis, abscesses and wound infections The susceptibility of the causative organism(s) to Cefoxitin for Injection should be determined by conducting appropriate culture and susceptibility studies. Therapy may be initiated while awaiting these test results. Adjustments in treatment may be required once these results become available. Organisms particularly appropriate for therapy with Cefoxitin for Injection are: Gram positive Staphylococci: penicillinase producing and non-producing Streptococci excluding enterococci Gram negative (beta-lactamase producing and non-producing strains) E. coli Klebsiella species (including K. pneumoniae)… https://pdf.hres.ca/dpd_pm/00073366.PDF PM date: November 16, 2023 Source product: CEFOXITIN FOR INJECTION; DIN 02128187; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Cefoxitin for Injection USP, Cefoxitin for Injection, Mefoxin: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026